PART B - FEE(S) TRANSMITTAL

plete and sand this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 MAR 2 1 2007 Alexandria, Virginia 22313-1450 or Fax (571)-273-2885 INSCLUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated the current correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) have its own certificate of mailing or transmission. 30405 7590 12/26/2006 Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. MILLENNIUM PHARMACEUTICALS, INC. 40 Landsdowne Street CAMBRIDGE, MA 02139 03/21/2007 EAYALEW2 00000049 501668 10678872 Sean/Hunziker/Beverly SotiropoulogDepositor's name (Signature 01 FC:1501 1400.00 DA 02 FC:1504 300.00 DA March (Date 9.00 DA 03 FC:8001 APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/678,872 10/03/2003 Shomir Ghosh 1855.2044-001 1269 TITLE OF INVENTION: PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES APPLN. TYPE SMALL ENTITY **ISSUE FEE DUE** PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE NO \$1400 \$300 nonprovisional \$0 \$1700 03/26/2007 **EXAMINER** ART UNIT CLASS-SUBCLASS SEAMAN, D MARGARET M 1625 546-157000 Millennium Pharmaceutical: 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, Inc. Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer 2 registered patent attorneys or agents. If no name is Number is required. listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE Millennium Pharmaceuticals, Inc. Cambridge, Massachusetts Please check the appropriate assignee category or categories (will not be printed on the patent): 🔲 Individual 🚨 Corporation or other private group entity 🔲 Government 4a. The following fee(s) are submitted: 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) Issue Fee A check is enclosed. ☑ Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. Advance Order - # of Copies The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 50 1608 (enclose an extra copy of this form). 501668 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. March 5, 2007 arolea

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Typed or printed name _ Karoline K. M. Shair

Authorized Signature

44,332

Registration No.

PATENT ket No. MPI02-110P1RNRCEM actitioner's l THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shomir Ghosh, et al.

Confirmation No. 1269

Serial No.:

10/678,872

Group No.: 1625

Filed:

October 3, 2003

Examiner:

Margaret D. Seaman

For:

PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF

INFLAMMATORY DISEASES

MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL OF PAYMENT OF ISSUE FEE (37 C.F.R. SECTION 1.311)

- 1. Transmitted herewith for this application are:
 - This Transmittal Letter (2 pages in duplicate);
 - PTOL-85 Part B Fee(s) Transmittal (1 page in duplicate); and b.
 - Return receipt postcard c.
- 2. Issue/Publication Fees (37 C.F.R. Section 1.18(a)):

Regular \$1,400.00 Application status is other than a small entity—fee: \$300.00 Publication fee \$9.00 Advance Copies of Patent (3)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service in an envelope addressed to the Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. \boxtimes

as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office

Signature

Sean Hunziker/Beverly Sotiropoulos

Date: March 5, 2007 (type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MPI02-110P1RNRCEM

3. Payment of fee:

Charge Account No. 501668 the sum of \$1,709.00. A duplicate of this request is attached. If any additional fee is required, charge Account No. 501668.

March 5, 2007

MILLENNIUM PHARMACEUTICALS, INC.

Βv

Karoline K. M. Shair, Ph.D. Registration No. 44,332 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-444-3227

Facsimile - 617-551-8820